Subscribe to the gold package and get unlimited access to Shamra Academy
Register a new userUltrasmall Glutathione-Protected Gold Nanoclusters as Next Generation Radiotherapy Sensitizers with High Tumor Uptake and High Renal Clearance
131
0
0.0
(
0
)
Ask ChatGPT about the research
No Arabic abstract
Radiotherapy is often the most straightforward first line cancer treatment for solid tumors. While it is highly effective against tumors, there is also collateral damage to healthy proximal tissues especially with high doses. The use of radiosensitizers is an effective way to boost the killing efficacy of radiotherapy against the tumor while drastically limiting the received dose and reducing the possible damage to normal tissues. Here, we report the design and application of a good radiosensitizer by using ultrasmall gold nanoclusters with a naturally occurring peptide (e.g., glutathione or GSH) as the protecting shell. The GSH coated gold nanoclusters can escape the RES absorption, leading to a good tumor uptake (8.1% ID/g at 24 h post injection). As a result, the as-designed Au nanoclusters led to a strong enhancement for radiotherapy, as well as a negligible damage to normal tissues. After the treatment, the ultrasmall gold nanoclusters can be efficiently cleared by the kidney, thereby avoiding potential long term side effects caused by the accumulation of gold atoms in the body. Our data suggest that the ultrasmall peptide protected Au nanoclusters are a promising radiosensitizer for cancer radiotherapy.
rate research
Read More
Radiosensitizers can increase the local treatment efficacy under a relatively low and safe radiation dose, thereby facilitating tumor eradication and minimizing side effects. Here, we report a new class of radiosensitizers that contain several gold (Au) atoms embedded inside a peptide shell (e.g., Au10-12(SG)10-12) and can achieve ultrahigh tumor uptake (10.86 SUV at 24 h post injection) and targeting specificity, efficient renal clearance, and high radiotherapy enhancement.
Ultrasmall gold nanoclusters show great potential in biomedical applications. Long term biodistribution, retention, toxicity, and pharmacokinetics profiles are prerequisites in their potential clinical applications. Here we systematically investigated the biodistribution, clearance, and toxicity of one widely used Au NC species glutathione protected Au NCs or GSH Au NCs, over a relatively long period of 90 days in mice. We observed that most of the Au NCs were cleared at 30 days post injection with a major accumulation in liver and kidney. However, it is surprising that an abnormal increase of Au amount in the heart, liver, spleen, lung, and testis was observed at 60 and 90 days, indicating that the injected Au NCs formed a V shaped time dependent distribution profile in various organs. Further investigations revealed that Au NCs were steadily accumulating in the muscle in the first 30 days p.i., and the as stored Au NCs gradually released into blood in 30 to 90 days, which induced a redistribution and reaccumulation of Au NCs in all blood rich organs. Further hematology and biochemistry studies showed that the reaccumulation of Au NCs still caused some liver toxicity at 30 days p.i. The muscle storage and subsequent release may give rise to the potential accumulation and toxicity risk of functional nanomaterials over long periods of time.
Diffuse low grade gliomas are slowly growing tumors that always recur after treatment. In this paper, we revisit the modeling of the tumor radius evolution before and after the radiotherapy process and propose a novel model that is simple, yet biologically motivated, and that remedies some shortcomings of previously proposed ones. We confront it with clinical data consisting in time-series of tumor radius for 43 patient records, using a stochastic optimization technique and obtain very good fits in all the cases. Since our model describes the evolution of the tumor from the very first glioma cell, it gives access to the possible age of the tumor. Using the technique of profile-likelihood to extract all the information from the data, we build confidence intervals for the tumor birth age and confirm the fact that low-grade glioma seem to appear in the late teenage years. Moreover, an approximate analytical expression of the temporal evolution of the tumor radius allows us to explain the correlations observed in the data.
Label-free imaging approaches seek to simplify and augment histopathologic assessment by replacing the current practice of staining by dyes to visualize tissue morphology with quantitative optical measurements. Quantitative phase imaging (QPI) operates with visible/UV light and thus provides a resolution matched to current practice. Here we introduce and demonstrate confocal QPI for label-free imaging of tissue sections and assess its utility for manual histopathologic inspection. Imaging cancerous and normal adjacent human breast and prostate, we show that tissue structural organization can be resolved with high spatial detail comparable to conventional H&E stains. Our confocal QPI images are found to be free of halo, solving this common problem in QPI. We further describe and apply a virtual imaging system based on Finite-Difference Time-Domain (FDTD) calculations to quantitatively compare confocal with wide-field QPI methods and explore performance limits using numerical tissue phantoms.
A novel radio guided surgery (RGS) technique for cerebral tumors using $beta^{-}$ radiation is being developed. Checking the availability of a radio-tracer that can deliver a $beta^{-}$ emitter to the tumor is a fundamental step in the deployment of such technique. This paper reports a study of the uptake of 90Y labeled (DOTATOC) in the meningioma and the high grade glioma (HGG) and a feasibility study of the RGS technique in these cases.
Log in to be able to interact and post comments
comments
Fetching comments
Sign in to be able to follow your search criteria
